Privium Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Privium Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-119,000	Closed	-$581K	–	64
2025 Q3	$581K	Hold	119,000	–	–	0.1%	49
2025 Q2	$610K	Hold	119,000	–	–	0.13%	44
2025 Q1	$630K	Hold	119,000	–	–	0.16%	38
2024 Q4	$804K	Buy	119,000 +41,000	+53%	+$276K	0.18%	37
2024 Q3	$514K	Buy	78,000 +26,000	+50%	+$186K	0.13%	49
2024 Q2	$372K	Buy	+52,000	New	+$454K	0.1%	63

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Privium Fund Management's RXRX Position: Q4 2025 in Review

Privium Fund Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 119,000 shares — an estimated $581K sold.

Privium Fund Management first reported a position in RXRX in Q2 2024 and held it in 6 quarters. The position peaked at $804K in Q4 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Privium Fund Management reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Privium Fund Management sold 119,000 Recursion Pharmaceuticals shares in Q4 2025, an estimated $581K.
Privium Fund Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Privium Fund Management's Recursion Pharmaceuticals position peaked at $804K in Q4 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Privium Fund Management's 13F filing for Q4 2025, filed 3 Feb 2026.